Ziarco Group is a privately held biotechnology company focused on treatments for inflammatory skin disorders.
Through the deal, Novartis will gain access to Ziarco’s investigational oral treatment for moderate-to-severe eczema.
Financial details of the transaction were not disclosed.
More articles on supply chain:
McKesson, Infor form go-to-market partnership: 3 things to know
American Red Cross needs donors amid seasonal blood shortage
Amazon conducts first drone delivery to a customer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
